Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 217

1.

Do tourniquet and drainage influence fast track in total knee arthroplasty? Our results on 151 cases.

Concina C, Crucil M, Fabbro S, Gherlinzoni F.

Acta Biomed. 2019 Jan 10;90(1-S):123-129. doi: 10.23750/abm.v90i1-S.8080.

2.

Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.

Filì C, Candoni A, Zannier ME, Olivieri J, Imbergamo S, Caizzi M, Nadali G, Di Bona E, Ermacora A, Gottardi M, Facchinelli D, Ciancia R, Lazzarotto D, Dubbini MV, Festini G, Gherlinzoni F, Michieli MG, Semenzato G, Fanin R.

Leuk Res. 2019 Jan;76:33-38. doi: 10.1016/j.leukres.2018.11.015. Epub 2018 Nov 28.

PMID:
30529681
3.

Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia.

Bettiol A, Marconi E, Lombardi N, Crescioli G, Gherlinzoni F, Walley T, Vannacci A, Chinellato A, Giusti P.

Clin Drug Investig. 2018 Sep;38(9):837-844. doi: 10.1007/s40261-018-0676-7.

PMID:
30043130
4.

A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.

Olivieri J, Mosna F, Pelosini M, Fama A, Rattotti S, Giannoccaro M, Carli G, Tisi MC, Ferrero S, Sgherza N, Mazzone AM, Marino D, Calimeri T, Loseto G, Saraceni F, Tomei G, Sica S, Perali G, Codeluppi K, Billio A, Olivieri A, Orciuolo E, Matera R, Stefani PM, Borghero C, Ghione P, Cascavilla N, Lanza F, Chiusolo P, Finotto S, Federici I, Gherlinzoni F, Centurioni R, Fanin R, Zaja F; Fondazione Italiana Linfomi Postgraduate Master Course.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1814-1822. doi: 10.1016/j.bbmt.2018.05.018. Epub 2018 May 29.

5.

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients.

Tiribelli M, Bonifacio M, Binotto G, Iurlo A, Cibien F, Maino E, Guella A, Festini G, Minotto C, De Biasi E, De Marchi F, Scaffidi L, Frison L, Bucelli C, Medeot M, Calistri E, Sancetta R, Stulle M, Orofino N, Krampera M, Gherlinzoni F, Semenzato G, Pizzolo G, Ambrosetti A, Fanin R.

Oncotarget. 2018 Feb 12;9(18):14219-14227. doi: 10.18632/oncotarget.24478. eCollection 2018 Mar 6.

6.

Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.

Candoni A, Papayannidis C, Martinelli G, Simeone E, Gottardi M, Iacobucci I, Gherlinzoni F, Visani G, Baccarani M, Fanin R.

Am J Hematol. 2018 May;93(5):655-663. doi: 10.1002/ajh.25057. Epub 2018 Mar 2.

7.

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.

Pellegrini C, Broccoli A, Pulsoni A, Rigacci L, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Santoro A, Hoaus S, Rigolin GM, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Ronconi F, Gritti G, Vallisa D, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Bianchi MP, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Carella AM, Stefoni V, Argnani L, Zinzani PL.

Oncotarget. 2017 May 23;8(53):91703-91710. doi: 10.18632/oncotarget.18114. eCollection 2017 Oct 31.

8.

Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia.

Gottardi M, Mosna F, de Angeli S, Papayannidis C, Candoni A, Clavio M, Tecchio C, Piccin A, dell'Orto MC, Benedetti F, Martinelli G, Gherlinzoni F.

Hematol Rep. 2017 Sep 26;9(3):7029. doi: 10.4081/hr.2017.7028. eCollection 2017 Sep 26. No abstract available.

9.

Carbon-fiber reinforced intramedullary nailing in musculoskeletal tumor surgery: a national multicentric experience of the Italian Orthopaedic Society (SIOT) Bone Metastasis Study Group.

Piccioli A, Piana R, Lisanti M, Di Martino A, Rossi B, Camnasio F, Gatti M, Maniscalco P, Gherlinzoni F, Spinelli MS, Donati DM, Biagini R, Capanna R, Denaro V; Italian Orthopaedic Society (SIOT) Bone Metastasis Study Group.

Injury. 2017 Oct;48 Suppl 3:S55-S59. doi: 10.1016/S0020-1383(17)30659-9.

PMID:
29025611
10.

Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.

Broccoli A, Pellegrini C, Di Rocco A, Puccini B, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Carlo-Stella C, Hohaus S, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Gravetti A, Gritti G, Arcari A, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Naso V, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Storti S, Carella AM, Stefoni V, Argnani L, Zinzani PL.

Haematologica. 2017 Nov;102(11):1931-1935. doi: 10.3324/haematol.2017.171355. Epub 2017 Aug 3.

11.

Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma.

Lacognata C, Crimì F, Guolo A, Varin C, De March E, Vio S, Ponzoni A, Barilà G, Lico A, Branca A, De Biasi E, Gherlinzoni F, Scapin V, Bissoli E, Berno T, Zambello R.

Clin Radiol. 2017 Oct;72(10):850-857. doi: 10.1016/j.crad.2017.05.004. Epub 2017 Jun 3.

PMID:
28587715
12.

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.

Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G; GIMEMA CML Working Party.

Am J Hematol. 2017 Aug;92(8):797-805. doi: 10.1002/ajh.24774. Epub 2017 May 30.

13.

Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.

Perricone M, Palandri F, Ottaviani E, Angelini M, Bagli L, Bellesia E, Donati M, Gemmati D, Zucchini P, Mancini S, Marchica V, Trubini S, De Matteis G, Di Zacomo S, Favarato M, Fioroni A, Bolzonella C, Maccari G, Navaglia F, Gatti D, Toffolatti L, Orlandi L, Laloux V, Manfrini M, Galieni P, Giannini B, Tieghi A, Barulli S, Serino ML, Maccaferri M, Scortechini AR, Giuliani N, Vallisa D, Bonifacio M, Accorsi P, Salbe C, Fazio V, Gusella M, Toffoletti E, Salvucci M, Svaldi M, Gherlinzoni F, Cassavia F, Orsini F, Martinelli G.

Oncotarget. 2017 May 16;8(20):32608-32617. doi: 10.18632/oncotarget.15940.

14.

Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia.

Piccin A, Steurer M, Feistritzer C, Murphy C, Eakins E, Van Schilfgaarde M, Corvetta D, Di Pierro AM, Pusceddu I, Marcheselli L, Gambato R, Langes M, Veneri D, Perbellini O, Pacquola E, Gottardi M, Gherlinzoni F, Mega A, Tauber M, Mazzoleni G, Piva E, Plebani M, Krampera M, Gastl G.

Transl Res. 2017 Jun;184:21-34. doi: 10.1016/j.trsl.2017.02.001. Epub 2017 Feb 14.

PMID:
28259616
15.

Two novel missense mutations in EPOR gene causes erythrocytosis in two unrelated patients.

Peroni E, Bertozzi I, Gherlinzoni F, Stefani PM, Lombardi A, Biagetti G, Fabris F, Randi ML.

Br J Haematol. 2018 Mar;180(6):908-911. doi: 10.1111/bjh.14486. Epub 2016 Dec 16. No abstract available.

PMID:
27982410
16.

Adrenomedullin in the growth modulation and differentiation of acute myeloid leukemia cells.

Di Liddo R, Bridi D, Gottardi M, De Angeli S, Grandi C, Tasso A, Bertalot T, Martinelli G, Gherlinzoni F, Conconi MT.

Int J Oncol. 2016 Apr;48(4):1659-69. doi: 10.3892/ijo.2016.3370. Epub 2016 Feb 2.

PMID:
26847772
17.

Psychological screening of onco-hematologic inpatients: Distress Thermometer administration.

Bellè M, Muzzatti B, Tomas M, Gherlinzoni F.

Tumori. 2016 Mar-Apr;102(2):178-83. doi: 10.5301/tj.5000440. Epub 2015 Oct 5.

PMID:
26439150
18.

Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy.

Lazzarotto D, Candoni A, Nadali G, Pavan L, Lessi F, Mosna F, Simeone E, Ventura G, Gherlinzoni F, Semenzato G, Pizzolo G, Fanin R.

Eur J Haematol. 2016 Jun;96(6):586-92. doi: 10.1111/ejh.12635. Epub 2015 Aug 17.

PMID:
26186084
19.

Prognostic value of PET/CT in patients with lymphoma treated with autologous stem cell transplantation for relapsed/refractory or high risk disease.

Stefani PM, Salvadori U, Gottardi M, Bissoli S, Chierichetti F, Gherlinzoni F.

Q J Nucl Med Mol Imaging. 2019 Mar;63(1):62-67. doi: 10.23736/S1824-4785.17.02793-5. Epub 2015 Jun 23.

PMID:
26101430
20.

Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.

Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, Pregno P, Rossi G, Gherlinzoni F, Leoni P, Cavazzini F, Venturi C, Soverini S, Testoni N, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party.

Leukemia. 2015 Sep;29(9):1823-31. doi: 10.1038/leu.2015.152. Epub 2015 Jun 19.

PMID:
26088952
21.

Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.

Mosna F, Papayannidis C, Martinelli G, Di Bona E, Bonalumi A, Tecchio C, Candoni A, Capelli D, Piccin A, Forghieri F, Bigazzi C, Visani G, Zambello R, Zanatta L, Volpato F, Paolini S, Testoni N, Gherlinzoni F, Gottardi M.

Am J Hematol. 2015 Jun;90(6):515-23. doi: 10.1002/ajh.24000. Epub 2015 Apr 1.

22.

Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia.

Piccin A, Steurer M, Mitterer M, Blöchl EM, Marcheselli L, Pusceddu I, Marabese A, Bertozzi I, Corvetta D, Randi ML, Elli E, Pogliani EM, Veneri D, Perbellini O, Krampera M, Pacquola E, Gottardi M, Tiribelli M, Guella A, Innella B, Vivaldi P, De Biasi E, Sancetta R, Rocconi R, Bassan R, Gherlinzoni F, Pizzolo G, Gastl G, Cortelazzo S.

Intern Emerg Med. 2015 Jun;10(4):451-60. doi: 10.1007/s11739-015-1186-8. Epub 2015 Jan 14.

PMID:
25585678
23.

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.

Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Gonella R, Gobbi M, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Loscocco F, Isidori A.

Blood. 2014 Nov 6;124(19):3029-31. doi: 10.1182/blood-2014-08-596668. No abstract available.

PMID:
25377565
24.

MGMT promoter methylation and correlation with protein expression in primary central nervous system lymphoma.

Toffolatti L, Scquizzato E, Cavallin S, Canal F, Scarpa M, Stefani PM, Gherlinzoni F, Dei Tos AP.

Virchows Arch. 2014 Nov;465(5):579-86. doi: 10.1007/s00428-014-1622-6. Epub 2014 Jul 17.

PMID:
25031012
25.

Prognostic significance of circulating and endothelial progenitor cell markers in type 2 diabetic foot.

Sambataro M, Seganfreddo E, Canal F, Furlan A, Del Pup L, Niero M, Paccagnella A, Gherlinzoni F, Dei Tos AP.

Int J Vasc Med. 2014;2014:589412. doi: 10.1155/2014/589412. Epub 2014 Feb 3.

26.

Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group.

Gronchi A, Colombo C, Le Péchoux C, Dei Tos AP, Le Cesne A, Marrari A, Penel N, Grignani G, Blay JY, Casali PG, Stoeckle E, Gherlinzoni F, Meeus P, Mussi C, Gouin F, Duffaud F, Fiore M, Bonvalot S; ISG and FSG.

Ann Oncol. 2014 Mar;25(3):578-83. doi: 10.1093/annonc/mdt485. Epub 2013 Dec 9.

27.

EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia.

Tiribelli M, Bonifacio M, Calistri E, Binotto G, Maino E, Marin L, Guardalben E, Branca A, Gherlinzoni F, Semenzato G, Sancetta R, Pizzolo G, Fanin R.

Leuk Res. 2013 Nov;37(11):1457-60. doi: 10.1016/j.leukres.2013.07.037. Epub 2013 Aug 11.

PMID:
23993428
28.

Familial hemophagocytic lymphohistiocytosis may present during adulthood: clinical and genetic features of a small series.

Sieni E, Cetica V, Piccin A, Gherlinzoni F, Sasso FC, Rabusin M, Attard L, Bosi A, Pende D, Moretta L, Aricò M.

PLoS One. 2012;7(9):e44649. doi: 10.1371/journal.pone.0044649. Epub 2012 Sep 7.

29.

Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study.

Efficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M, Alimena G, Iurlo A, Rossi AR, Pardini S, Gherlinzoni F, Salvucci M, Tiribelli M, Vignetti M, Mandelli F.

Br J Cancer. 2012 Sep 4;107(6):904-9. doi: 10.1038/bjc.2012.348. Epub 2012 Aug 7.

30.

Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.

Iacobucci I, Lonetti A, Candoni A, Sazzini M, Papayannidis C, Formica S, Ottaviani E, Ferrari A, Michelutti A, Simeone E, Astolfi A, Abbenante MC, Parisi S, Cattina F, Malagola M, Russo D, Damiani D, Gherlinzoni F, Gottardi M, Baccarani M, Fanin R, Martinelli G.

Pharmacogenomics J. 2013 Aug;13(4):335-41. doi: 10.1038/tpj.2012.13. Epub 2012 May 15.

PMID:
22584460
31.

Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia.

Todeschini G, Bonifacio M, Tecchio C, Balter R, Carli G, Stefani PM, Adami F, Zamò A, Dei Tos AP, Marino F, Gherlinzoni F, Marradi P, Semenzato G, Pizzolo G.

Am J Hematol. 2012 Jan;87(1):22-5. doi: 10.1002/ajh.22189. Epub 2011 Nov 16.

32.

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.

Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Giardini C, Falcioni S, Cuberli F, Gobbi M, Sarina B, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Isidori A.

Blood. 2011 Sep 22;118(12):3419-25. doi: 10.1182/blood-2011-04-351924. Epub 2011 Aug 3.

PMID:
21816830
33.

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party.

Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, Martino B, Pregno P, Rupoli S, Ferrero D, Gherlinzoni F, Montefusco E, Bocchia M, Tiribelli M, Pierri I, Grifoni F, Marzocchi G, Amabile M, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M, Rosti G; Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party.

Blood. 2011 May 26;117(21):5591-9. doi: 10.1182/blood-2010-12-324228. Epub 2011 Mar 30.

PMID:
21450900
34.

What does preemptive antifungal treatment really mean?

Stefani PM, Salvadori U, Gottardi M, Rigoli R, Scotton P, Gherlinzoni F.

Clin Infect Dis. 2010 Apr 15;50(8):1201-2; author reply 1202. doi: 10.1086/651470. No abstract available.

PMID:
20233047
35.

Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior.

Forconi F, Sozzi E, Cencini E, Zaja F, Intermesoli T, Stelitano C, Rigacci L, Gherlinzoni F, Cantaffa R, Baraldi A, Gallamini A, Zaccaria A, Pulsoni A, Gobbi M, Tassi M, Raspadori D, Leoncini L, Rinaldi A, Sabattini E, Bertoni F, Pileri SA, Lauria F.

Blood. 2009 Nov 19;114(21):4696-702. doi: 10.1182/blood-2009-03-212449. Epub 2009 Aug 10.

PMID:
19667403
36.

Cytogenetic evidence of metastatic myxoid liposarcoma and therapy-related myelodysplastic syndrome in a bone marrow biopsy.

Rossi S, Canal F, Licci S, Zanatta L, Laurino L, Gottardi M, Gherlinzoni F, Dei Tos AP.

Hum Pathol. 2009 Jul;40(7):1040-4. doi: 10.1016/j.humpath.2008.12.020. Epub 2009 May 12.

PMID:
19439345
37.

Complete remission induced by thalidomide in a case of angioimmunoblastic T-cell lymphoma refractory to autologous stem cell transplantation.

Gottardi M, Danesin C, Canal F, Dei Tos AP, Stefani PM, Calistri E, Salvadori U, Gherlinzoni F.

Leuk Lymphoma. 2008 Sep;49(9):1836-8. doi: 10.1080/10428190802233165. No abstract available.

PMID:
18661402
38.

Aleukemic granulocytic sarcoma with associated T-cell lymphoblastic lymphoma in the same lymph node: morphologic features and molecular signatures.

Licci S, Canal F, Dei Tos AP, Fedrigo M, Gherlinzoni F, Brenna A, Zanatta L, Rossi S.

Leuk Lymphoma. 2008 Jul;49(7):1411-5. doi: 10.1080/10428190802108862. No abstract available.

PMID:
18604727
39.

Primary cardiac onset of disseminated Burkitt's lymphoma.

Stefani PM, Laurino L, Zanatta L, Valori L, dei Tos AP, Gherlinzoni F.

Ann Hematol. 2008 Jun;87(6):487-8. Epub 2007 Dec 8. No abstract available.

PMID:
18066547
40.

Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group.

Grimer RJ, Gosheger G, Taminiau A, Biau D, Matejovsky Z, Kollender Y, San-Julian M, Gherlinzoni F, Ferrari C.

Eur J Cancer. 2007 Sep;43(14):2060-5. Epub 2007 Aug 27.

PMID:
17720491
41.

High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma.

Tecchio C, Nadali G, Scapini P, Bonetto C, Visco C, Tamassia N, Vassilakopoulos TP, Pangalis GA, Calzetti F, Nardelli B, Roschke V, Gottardi M, Zampieri F, Gherlinzoni F, Facchetti F, Pizzolo G, Cassatella MA.

Br J Haematol. 2007 Jun;137(6):553-9.

PMID:
17539776
42.

Rekonstruktion der Brustwand nach Resektion ausgedehnter Tumoren.

Briccoli A, Manfrini M, Gherlinzoni F, Fabbri N, Mercuri M.

Oper Orthop Traumatol. 1998 Sep;10(3):176-82. German. No abstract available.

PMID:
17003969
43.

Concomitant chronic lymphocytic leukemia and acute myeloid leukemia: evidence of simultaneous expansion of two independent clones.

Gottardi M, Gattei V, Degan M, Bomben R, Zucchetto A, Tecchio C, Laurino L, Zanatta L, Dei Tos AP, Mordacchini M, Canal F, Gherlinzoni F.

Leuk Lymphoma. 2006 May;47(5):885-9.

PMID:
16753874
44.

Adjuvant treatment of high-risk adult soft tissue sarcomas: a survey by the Italian Sarcoma Group.

Frustaci S, Berretta M, Comandone A, Bidoli E, De Paoli A, Gherlinzoni F, De Pas T, Barbieri E, Pertici M, Apice G, Picci P; Italian Sarcoma Group.

Tumori. 2006 Mar-Apr;92(2):92-7.

PMID:
16724686
45.

Preemptive antifungal therapy among neutropenic patients.

Stefani PM, Gottardi M, Zanetti F, Tecchio C, Sartor D, Gherlinzoni F.

Clin Infect Dis. 2006 May 15;42(10):1507-8; author reply 1508-9. No abstract available.

PMID:
16619177
46.

Imatinib and hyperlipidemia.

Gottardi M, Manzato E, Gherlinzoni F.

N Engl J Med. 2005 Dec 22;353(25):2722-3. No abstract available.

PMID:
16371644
47.

The evolution of integrated treatment of soft tissue sarcoma at the Rizzoli Orthopaedic Institute.

Gherlinzoni F, Picci P, Mercuri M, Bacci G, Frustaci S, De Paoli A, Barbieri E.

Chir Organi Mov. 2004 Apr-Jun;89(2):95-105. English, Spanish.

PMID:
15645786
48.

Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients.

Isidori A, Bonifazi F, Visani G, Gherlinzoni F, Baccarani M, Lemoli RM.

Haematologica. 2005 Jan;90(1):139-41.

49.

High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience.

Zinzani PL, Tani M, Gabriele A, Gherlinzoni F, De Vivo A, Ricci P, Bandini G, Lemoli RM, Motta MR, Rizzi S, Guidice V, Zompatori M, Stefoni V, Alinari L, Musuraca G, Marchi E, Bassi S, Conte R, Pileri S, Tura S, Baccarani M.

Leuk Lymphoma. 2004 Feb;45(2):321-6.

PMID:
15101718
50.

Babesia infection in Italy.

Piccaluga PP, Poletti G, Martinelli G, Gherlinzoni F.

Lancet Infect Dis. 2004 Apr;4(4):212. No abstract available.

PMID:
15050938

Supplemental Content

Loading ...
Support Center